Saturday 17 October 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
In the quarter to June 2026, EPS fell 34.5% and free cash flow fell 29.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
49.61
1.10
−2.17%
Follow MBX
MBX Biosciences, Inc. (MBX) P/E ratio
MBX Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NAMS NewAmsterdam Pharma Company N.V. compare | n/m |
| SLS SELLAS Life Sciences Group, Inc. compare | n/m |
| MBX MBX Biosciences, Inc. | n/m |
| BEAM Beam Therapeutics Inc. compare | n/m |
| ZLAB Zai Lab Limited Unsponsored ADR compare | n/m |
| CLDX Celldex Therapeutics, Inc. compare | n/m |
| PGEN Precigen, Inc. compare | n/m |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.9× |
| ADMA ADMA Biologics Inc compare | 14.8× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)